At 0.2 mg/kg doses, VEGFR-2+/CD31+ endothelial cells were depleted from tumor vasculature (Figure 6A), total numbers of VEGFR-2+ cells were reduced (Figure 6B) and total numbers of CD31+ cells were not changed (Figure 6C); similar to our experience with NCR athymic mice. This evidence concerns the gene PECAM1 and neoplasm.